David Katz


David is founder and CEO of Sparrow Pharmaceuticals, Inc., a clinical stage company that is developing next-generation corticosteroid medications. Previously he was a pharmaceutical R&D executive for 18 years at Abbott and AbbVie, where he led clinical trials and drug discovery teams, and was a pioneer in the field of personalized medicine. Dr. Katz has consulted for both the Food & Drug Administration and the National Institutes of Health.

David enjoys mentorship of life sciences companies. Since moving to Portland Oregon in 2018, he has been an entrepreneur-in-residence at Oregon Health Sciences University. As a member of Chicago Innovation Mentors, he advised nascent companies from the University of Chicago and the University of Illinois at Chicago. David is also an experienced angel investor (Keiretsu Forum, Chicago ArchAngels) who invests mainly in companies with potential to improve human health, mitigate anthropogenic climate change, or reduce socioeconomic inequality.

Dr. Katz was an Irvington Institute of Immunology post-doctoral fellow at the University of Chicago and a Howard Hughes Medical Institute post-doctoral fellow at the University of Michigan. David earned his Ph.D. in Molecular Biophysics and Biochemistry at Yale University, and is an alumnus of Pomona College (BA, Chemistry). He has published over 50 peer-reviewed research papers in top journals.

David is a glass artist and an avid theater goer. He was a Board Member and President of American Theater Company in Chicago. ATC premiered many new plays, including Disgraced by Ayad Akhtar (Pulitzer Prize) and The Humans by Stephen Karam (four Tony Awards).